Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Genetic Techniques May Lead to New Therapeutic Approaches for Cardiovascular Diseases

By BiotechDaily International staff writers
Posted on 19 Jun 2014
A review summarized the state-of-the-art in the field of genome-based therapies for cardiovascular diseases.

Despite statistics showing that the death rate from heart disease has fallen about 39% percent over the past 10 years, heart disease remains the number-one cause of death in the United States, killing almost 380,000 people a year. As several recent approaches to treating the wide range of heart diseases have failed for lack of efficacy, the author of the review, Dr. Daniel J. Rader, professor of genetics at the University of Pennsylvania (Philadelphia, USA) has suggested that human genetics-based technologies have the potential to identify new targets for which the likelihood of therapeutic success is considerably greater.

Among the problems he cited in the June 4, 2014, issue of the journal Science Translational Medicine were (1) many biopharmaceutical companies have begun to back away from efforts to discover and develop therapies for this prevalent disease; (2) seven drugs have failed in phase III clinical trials in the last three to five years; and (3) animal models of atherosclerosis have not proven reliable at predicting new therapies that are effective in humans.

Dr. Rader suggested that as with recent successes in cancer immunotherapy, basing drug targets on human genetics may provide greater confidence that a therapeutic targeted to a particular pathway will show clinical benefit in reducing major cardiovascular events in people. In the review he cited studies of common variants associated with cardiovascular diseases that had yielded nearly 50 statistically significantly associated discrete genetic loci genome-wide. Less than a third were associated with such traditional risk factors as LDL-C (low density lipoprotein-cholesterol) levels or blood pressure, leaving more than 30 loci with no association with traditional measureable risk factors.

"Some of the most interesting new targets for atherosclerotic cardiovascular disease are likely to come from genetic studies of common and rare variants, comparing individuals with early disease with those who are free of disease," said Dr. Rader.

Related Links:
University of Pennsylvania



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.